Developer docs
API playgroundTry for free, no card

Search company profiles

IDEA Pharma

Full company profile

uuid000bs5s

Namestring
IDEA Pharma
Legal namestring
IDEA Pharma, a division of SAI MedPartners
Websiteurl
ideapharma.com
Company typeenum
Private
Founded yearint
1999
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical strategy consulting, biopharma positioning strategy, path-to-market strategy, pharma innovation benchmarking, virtual chief commercial officer
Industry1 code
PRIMARYMPAAAAAJ
Healthcare/Pharma Creative Agencies
Media, Entertainment & Sports/Advertising, Marketing & PR Services/Advertising Agencies (Full-Service/Creative)
NAICS code2 codes
  • Management Consulting Services54161
  • Marketing Consulting Services541613
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Pharmaceutical Strategy Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

IDEA Pharma generates revenue through providing strategic consultancy services to pharmaceutical and biotech companies. Services include positioning strategy, path-to-market strategy, commercial strategy development, and decision intelligence. The company operates on a project-based consulting model with fees for strategic advisory engagements.

ideapharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Pharmaceutical Innovation and Invention Index
Description

Annual ranking of the world's leading pharma companies by their ability to create new ideas and turn them into value, now in its 15th year

ideapharma.com
+5 more records
Core offering1 text field

IDEA Pharma is a strategic consultancy that delivers positioning and path-to-market strategy for biopharma clients from early through late phase development. Offerings include Strategic Positioning Services, Path-to-Market Strategy engagements, and a virtual Chief Commercial Officer (vCCO) service for biotech companies. The firm also publishes the annual Global Pharmaceutical Innovation and Invention Index, Digital Innovation Index, and China Pharmaceutical Innovation Index as proprietary research benchmarks.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IDEA Pharma is a strategic consultancy (division of SAI MedPartners) providing pharmaceutical innovation expertise, path-to-market strategy, and decision intelligence services. Their core offerings include the Global Pharmaceutical Innovation and Invention Index (tracking top pharma companies' ability to develop and commercialize drugs), the Digital Innovation Index, and the China Pharmaceutical Index. Their Decision Intelligence Approach integrates cross-functional expertise (clinical, regulatory, commercial, analytics, medical) into a stepwise process. The vCCO (virtual Chief Commercial Officer) service provides biotech companies with CCO-level expertise without the full-time hire. Services include strategic positioning, path-to-market strategy, and commercial strategy development.

Product and service6 records
1Strategic Positioning Services
CategoryStrategic consulting service
Description

Best-in-class positioning services delivered to biopharma companies from early through late phase development, providing a robust positioning platform and strategic narrative for drug assets.

2Path-to-Market Strategy Services
CategoryStrategic consulting service
Description

Path-to-market strategy engagements that define how a biopharma asset will be commercialized, including market shaping, scenario planning, FIVE-X positioning options, and communications platform development.

3vCCO (virtual Chief Commercial Officer) Service
CategoryStrategic consulting service
Description

Provides biotech companies with the services traditionally performed by a chief commercial officer, combined with consultancy support from a cross-functional team including clinical, regulatory, analytics, medical, and commercial experts.

4Global Pharmaceutical Innovation and Invention Index
CategoryResearch index / publication
Description

Annual benchmark ranking the world's leading pharmaceutical companies by their ability to create new ideas and turn them into meaningful outcomes, measuring both invention (raw ideas) and innovation (commercial execution).

5Digital Innovation Index
CategoryResearch index / publication
Description

Annual index revealing how top pharmaceutical companies leverage digital advancements to accelerate development, improve patient engagement, and drive impactful change in healthcare.

6China Pharmaceutical Innovation Index
CategoryResearch index / publication
Description

Dedicated ranking for the fast-growing Chinese pharmaceutical market, tracking top pharmaceutical companies in China.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-20
Description

Strategic commercial partnership to advance path-to-market commercialization for Candel Therapeutics' lead asset CAN-2409. IDEA provides strategic commercial input throughout development and commercialization process, including commercial strategy development and support for BLA submission in prostate cancer. Partnership expected to run through 2026. Candel retains overall commercial strategy leadership while gaining access to IDEA's cross-functional team expertise in oncology commercialization.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialist life-sciences commercial strategy and insights firm serving pharma and biotech on launch, positioning, and competitive readiness. Closely comparable in service scope and customer segment to IDEA Pharma.

TypeDirect peer
Description

Boutique life-sciences strategy consultancy focused on asset-level commercial strategy, positioning, and launch planning for pharma and biotech. Highly comparable niche specialist competing for similar enterprise and biotech engagements.

3ZS Associates
TypeDirect peer
Description

Large global consulting firm deeply specialized in pharmaceutical and biotech commercial strategy, including sales force, launch, and positioning work. Direct competitor for the same enterprise pharma buyers and strategic-launch engagements.

TypeBroad incumbent
Description

Global strategy consultancy with a long-standing life-sciences specialization, particularly in commercial strategy and pipeline assessment. Directly comparable positioning work for enterprise pharma clients, though at much greater scale.

TypeBroad incumbent
Description

Global life-sciences technology and services incumbent offering commercial strategy, market access, and real-world evidence to pharma and biotech. Broader portfolio and much larger scale than IDEA but overlapping in positioning and launch strategy.

TypeDirect peer
Description

Parent company of IDEA Pharma since November 2024. Directly comparable as a life-sciences-focused commercial strategy consultancy offering market research, market access, pricing, and competitive intelligence alongside positioning work.

TypeDirect peer
Description

Global consultancy with deep life-sciences pricing, market access, and commercial strategy expertise. Overlaps directly with IDEA's positioning and path-to-market work, particularly at launch and BD&L stages.

TypeBroad incumbent
Description

Global consulting firm with a dedicated life-sciences practice advising on commercial strategy, pricing, and market access. Larger and broader than IDEA but competes in the same pharma/biotech strategic advisory space.

TypeBroad incumbent
Description

Global strategy incumbent with a dedicated pharma practice covering R&D, launch, and commercial strategy. Competes for the same enterprise pharma strategic mandates but at a much larger scale and broader scope than IDEA.

TypeBroad incumbent
Description

Global strategy incumbent with a dedicated biopharma practice advising on launch, portfolio, and commercial strategy. Competes for senior-level strategic engagements with the same large pharma clients as IDEA.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IDEA Pharma

Pharmaceutical Strategy Consultingideapharma.com

IDEA Pharma firmographics

Firmographics
Name
IDEA Pharma
Legal name
IDEA Pharma, a division of SAI MedPartners
Website
https://ideapharma.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

IDEA Pharma industry classification

Industry
Product category
Pharmaceutical Strategy Consulting
NAICS
Management Consulting Services (54161), Marketing Consulting Services (541613)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYMPAAAAAJ
Healthcare/Pharma Creative Agencies
Media, Entertainment & Sports/Advertising, Marketing & PR Services/Advertising Agencies (Full-Service/Creative)

Keywords

  • Pharmaceutical strategy consulting
  • Biopharma positioning strategy
  • Path-to-market strategy
  • Pharma innovation benchmarking
  • Virtual chief commercial officer

Where IDEA Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

IDEA Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Strategic Consulting Services: IDEA Pharma generates revenue through providing strategic consultancy services to pharmaceutical and biotech companies. Services include positioning strategy, path-to-market strategy, commercial strategy development, and decision intelligence. The company operates on a project-based consulting model with fees for strategic advisory engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

IDEA Pharma product offering

Product offering

Core offering

IDEA Pharma is a strategic consultancy that delivers positioning and path-to-market strategy for biopharma clients from early through late phase development. Offerings include Strategic Positioning Services, Path-to-Market Strategy engagements, and a virtual Chief Commercial Officer (vCCO) service for biotech companies. The firm also publishes the annual Global Pharmaceutical Innovation and Invention Index, Digital Innovation Index, and China Pharmaceutical Innovation Index as proprietary research benchmarks.

Product overview

IDEA Pharma is a strategic consultancy (division of SAI MedPartners) providing pharmaceutical innovation expertise, path-to-market strategy, and decision intelligence services. Their core offerings include the Global Pharmaceutical Innovation and Invention Index (tracking top pharma companies' ability to develop and commercialize drugs), the Digital Innovation Index, and the China Pharmaceutical Index. Their Decision Intelligence Approach integrates cross-functional expertise (clinical, regulatory, commercial, analytics, medical) into a stepwise process. The vCCO (virtual Chief Commercial Officer) service provides biotech companies with CCO-level expertise without the full-time hire. Services include strategic positioning, path-to-market strategy, and commercial strategy development.

Differentiator

Problem solved

Functional benefit

Brands

  • Pharmaceutical Innovation and Invention Index: Annual ranking of the world's leading pharma companies by their ability to create new ideas and turn them into value, now in its 15th year
  • Digital Innovation Index
  • China Pharmaceutical Innovation Index
  • Virtual Chief Commercial Officer (vCCO)
  • IDEA Collider Podcast
  • Deep Medicine Podcast

Products and services

  • Strategic Positioning Services Best-in-class positioning services delivered to biopharma companies from early through late phase development, providing a robust positioning platform and strategic narrative for drug assets.
  • Path-to-Market Strategy Services Path-to-market strategy engagements that define how a biopharma asset will be commercialized, including market shaping, scenario planning, FIVE-X positioning options, and communications platform development.
  • vCCO (virtual Chief Commercial Officer) Service Provides biotech companies with the services traditionally performed by a chief commercial officer, combined with consultancy support from a cross-functional team including clinical, regulatory, analytics, medical, and commercial experts.
  • Global Pharmaceutical Innovation and Invention Index Annual benchmark ranking the world's leading pharmaceutical companies by their ability to create new ideas and turn them into meaningful outcomes, measuring both invention (raw ideas) and innovation (commercial execution).
  • Digital Innovation Index Annual index revealing how top pharmaceutical companies leverage digital advancements to accelerate development, improve patient engagement, and drive impactful change in healthcare.
  • China Pharmaceutical Innovation Index Dedicated ranking for the fast-growing Chinese pharmaceutical market, tracking top pharmaceutical companies in China.

Companies that use IDEA Pharma

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

IDEA Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

IDEA Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Candel TherapeuticscoreStrategic or Co-development Partner · 20 March 2025Strategic commercial partnership to advance path-to-market commercialization for Candel Therapeutics' lead asset CAN-2409. IDEA provides strategic commercial input throughout development and commercialization process, including commercial strategy development and support for BLA submission in prostate cancer. Partnership expected to run through 2026. Candel retains overall commercial strategy leadership while gaining access to IDEA's cross-functional team expertise in oncology commercialization.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

IDEA Pharma competitors and assessment

Company assessment

Direct peers

  • Trinity Life Sciences: Specialist life-sciences commercial strategy and insights firm serving pharma and biotech on launch, positioning, and competitive readiness. Closely comparable in service scope and customer segment to IDEA Pharma.
  • Clearview Healthcare Partners: Boutique life-sciences strategy consultancy focused on asset-level commercial strategy, positioning, and launch planning for pharma and biotech. Highly comparable niche specialist competing for similar enterprise and biotech engagements.
  • ZS Associates: Large global consulting firm deeply specialized in pharmaceutical and biotech commercial strategy, including sales force, launch, and positioning work. Direct competitor for the same enterprise pharma buyers and strategic-launch engagements.
  • SAI MedPartners: Parent company of IDEA Pharma since November 2024. Directly comparable as a life-sciences-focused commercial strategy consultancy offering market research, market access, pricing, and competitive intelligence alongside positioning work.
  • Simon-Kucher & Partners (Life Sciences): Global consultancy with deep life-sciences pricing, market access, and commercial strategy expertise. Overlaps directly with IDEA's positioning and path-to-market work, particularly at launch and BD&L stages.

Broad incumbents

  • LEK Consulting (Life Sciences Practice): Global strategy consultancy with a long-standing life-sciences specialization, particularly in commercial strategy and pipeline assessment. Directly comparable positioning work for enterprise pharma clients, though at much greater scale.
  • IQVIA (Commercial Strategy & Analytics): Global life-sciences technology and services incumbent offering commercial strategy, market access, and real-world evidence to pharma and biotech. Broader portfolio and much larger scale than IDEA but overlapping in positioning and launch strategy.
  • Charles River Associates (Life Sciences Practice): Global consulting firm with a dedicated life-sciences practice advising on commercial strategy, pricing, and market access. Larger and broader than IDEA but competes in the same pharma/biotech strategic advisory space.
  • McKinsey & Company (Pharma & Medical Products Practice): Global strategy incumbent with a dedicated pharma practice covering R&D, launch, and commercial strategy. Competes for the same enterprise pharma strategic mandates but at a much larger scale and broader scope than IDEA.
  • Boston Consulting Group (Healthcare & Biopharma Practice): Global strategy incumbent with a dedicated biopharma practice advising on launch, portfolio, and commercial strategy. Competes for senior-level strategic engagements with the same large pharma clients as IDEA.

Market position

Strengths1 record

Competitive moat4 records

Customer concentration

IDEA Pharma social profiles

Digital presence

IDEA Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IDEA Pharma leadership team

Management profile

Number of profiles

Profiles3 records

IDEA Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IDEA Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDEA Pharma

What does IDEA Pharma do?

IDEA Pharma is a strategic consultancy that delivers positioning and path-to-market strategy for biopharma clients from early through late phase development. Offerings include Strategic Positioning Services, Path-to-Market Strategy engagements, and a virtual Chief Commercial Officer (vCCO) service for biotech companies. The firm also publishes the annual Global Pharmaceutical Innovation and Invention Index, Digital Innovation Index, and China Pharmaceutical Innovation Index as proprietary research benchmarks.

Is IDEA Pharma a public or private company?

IDEA Pharma is a private company. It is classified as corporate owned and is currently operating.

When was IDEA Pharma founded?

IDEA Pharma was founded in 1999. It employs 11 to 50 people.

Where is IDEA Pharma based?

IDEA Pharma is headquartered in London, United Kingdom, in the Europe region.

How does IDEA Pharma make money?

One revenue line is on record: strategic Consulting Services.

Who are IDEA Pharma's main competitors?

Direct peers on record are Trinity Life Sciences, Clearview Healthcare Partners, ZS Associates, SAI MedPartners and Simon-Kucher & Partners (Life Sciences). Broad incumbents are LEK Consulting (Life Sciences Practice), IQVIA (Commercial Strategy & Analytics), Charles River Associates (Life Sciences Practice), McKinsey & Company (Pharma & Medical Products Practice) and Boston Consulting Group (Healthcare & Biopharma Practice).

Does IDEA Pharma have an API?

No public API is recorded for IDEA Pharma.

What industry is IDEA Pharma in?

IDEA Pharma's product category is Pharmaceutical Strategy Consulting. Its primary akta.pro industry code is MPAAAAAJ, Healthcare/Pharma Creative Agencies. Its NAICS code is 54161 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmaVoiceWho’s winning pharma’s innovation race? The rankings are out.Idea Pharma released its annual Global Innovation and Invention indexes, ranking pharmaceutical companies on their ability to launch new drugs and develop new ones, with Eli Lilly becoming the first company to achieve the No. 1 position on both lists, driven by 45% revenue growth fueled by its weight loss drugs and $202 million acquisition of Engage Biologics. Several major pharma companies saw notable shifts in rankings, with Sanofi rising 19 places to No. 3 and GSK leaping 10 spots to No. 4, while Novo Nordisk fell out of the top 10 and both Pfizer and Bristol Myers Squibb continued to decline due to post-COVID challenges and clinical setbacks. Idea Pharma also introduced its first "Disruptive Pioneers" list highlighting 10 emerging biotechs with cutting-edge technologies, including Revolution Medicines, Parabilis Medicines, Intellia Therapeutics, Tune Therapeutics, and Compass Pathways, which are being developed with early commercialization strategies.SpringerLinkIdentification and Predictive Analysis of Revenue Determinants in the Pharma Industry: A Longitudinal Analysis of Financial, Regulatory and Pipeline DataA study utilizing IDEA Pharma’s longitudinal data from 2019 to 2023 analyzed the top 24 pharmaceutical companies to identify key determinants of future revenue. The research found that higher R&D spending, a lower proportion of R&D spend relative to current revenue, and a greater number of Phase III clinical trials are significant predictors of increased future earnings. This predictive model aims to assist pharma companies in strategic planning and managing financial resources amidst rising development costs.GlobeNewswireCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership to advance CAN-2409's path-to-market. The deal follows positive phase 3 data showing a 30% reduction in disease recurrence and an 80.4% pathological complete response rate. The partnership is expected to run through 2026.MorningstarCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership to advance CAN-2409's path-to-market. The deal follows positive phase 3 data showing a 30% reduction in disease recurrence and an 80.4% pathological complete response rate. The partnership is expected to run through 2026.Business InsiderCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership to advance CAN-2409's path-to-market. The deal follows positive phase 3 data showing a 30% reduction in disease recurrence and an 80.4% pathological complete response rate. The partnership is expected to run through 2026.Business InsiderCandel Therapeutics, IDEA Pharma announce strategic partnershipCandel Therapeutics and IDEA Pharma announced a strategic commercial partnership for Candel's lead asset CAN-2409. The deal follows positive phase 3 data showing a 30% decrease in disease recurrence and a statistically significant increase in pathological complete response rate in localized prostate cancer.Business Wire BlogSAI MedPartners Expands Strategic Service Offering Through Acquisition of IDEA PharmaSAI MedPartners acquired IDEA Pharma, a London-based firm specializing in pharmaceutical path-to-market strategy. The acquisition strengthens SAI's strategic services for biopharma clients, covering drug discovery to market launch. It is SAI's third strategic acquisition, following Fulcrum Research Group and PharmaForce International.FortuneIDEA Pharma: Pharmaceutical Invention & Innovation Index 2022IDEA Pharma released its 11th annual Pharmaceutical Innovation and Invention Index, ranking Pfizer first for its COVID vaccine and Paxlovid sales. Pfizer's vaccine accounted for 45% of its 2021 global revenue, while AstraZeneca and Regeneron also ranked highly. The index emphasizes long-term value over pandemic-driven gains.PR NewswireIDEA Pharma et Protodigm agrandissent et renforcent leur équipe avec des experts chevronnés du secteurIDEA Pharma and its sister company Protodigm announced the appointment of three industry experts—Dr. Jonathan Lee, Jeff Waldron, and Sayak "Sy" Mukherjee—to their team on September 20, 2021. The new hires bring expertise in medical strategy, business development, and communications to support early-stage drug commercialization projects for clients. The appointments reflect the companies' strategy to bring "creative discipline" and cross-industry experience to early-stage biotechnology development challenges.PR NewswireIDEA Pharma und Protodigm erweitern und verstärken ihr Team mit ausgewiesenen BranchenexpertenIDEA Pharma announced the appointment of three industry experts—Dr. Jonathan Lee, Jeff Waldron, and Sayak 'Sy' Mukherjee—to support its early-phase market launch strategies and its sister company Protodigm. Dr. Lee will serve as Medical Strategist with expertise from his MBA at Oxford and doctorate from Virginia Commonwealth University, while Waldron brings strategic and business development experience from his Wharton MBA. Mukherjee joins as Communications Architect, supporting both IDEA Pharma and Protodigm's CEO Mike Rea with communications and special projects.